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The provision of post-discharge malaria chemoprevention (PMC) in children recently admit-
ted with severe anemia reduces the risk of death and re-admissions in malaria endemic
countries. The main objective of this trial was to identify the most effective method of deliver-
ing dihydroartemesinin-piperaquine to children recovering from severe anemia.
Methods
This was a 5-arm, cluster-randomized trial among under-5 children hospitalized with severe
anemia at Zomba Central Hospital in Southern Malawi. Children were randomized to receive
three day treatment doses of dihydroartemesinin-piperaquine monthly either; 1) in the com-
munity without a short text reminder; 2) in the community with a short message reminder; 3)
in the community with a community health worker reminder; 4) at the facility without a short
text reminder; or 5) at the facility with a short message reminder. The primary outcome mea-
sure was adherence to all treatment doses of dihydroartemesinin-piperaquine and this was
assessed by pill-counts done by field workers during home visits. Poisson regression was
utilized for analysis.
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Results
Between March 2016 and October 2018, 1460 clusters were randomized. A total of 667 chil-
dren were screened and 375 from 329 clusters were eligible and enrolled from the hospital.
Adherence was higher in all three community-based compared to the two facility-based
delivery (156/221 [70�6%] vs. 78/150 [52�0%], IRR = 1�24,95%CI 1�06–1�44, p = 0�006).
This was observed in both the SMS group (IRR = 1�41,1�21–1�64, p<0�001) and in the non-
SMS group (IRR = 1�37,1�18–1�61, p<0�001). Although adherence was higher among SMS
recipients (98/148 66�2%] vs. non-SMS 82/144 (56�9%), there was no statistical evidence
that SMS reminders resulted in greater adherence ([IRR = 1�03,0�88–1�21, p = 0�68). When
compared to the facility-based non-SMS arm (control arm), community-based delivery utiliz-
ing CHWs resulted in higher adherence [39/76 (51�3%) vs. 54/79 (68�4%), IRR = 1�32,
1�14–1�54, p<0�001].
Interpretation
Community-based delivery of dihydroartemesinin-piperaquine for post-discharge malaria
chemoprevention in children recovering from severe anemia resulted in higher adherence




Severe anemia in under-five children is defined as low hemoglobin level of less than 7g/dl [1].
It affects over 10 million children globally and is one of the leading cause of pediatric hospital
admissions and mortality in sub-Saharan Africa (SSA) [2]. Children admitted to hospital with
severe anemia are at high risk of dying not only during the acute phase but also after discharge
from hospital [3,4]. One prospective study in Malawi reported that 8% of hospitalized children
with severe anemia were re-admitted or died within six months after discharge compared to
none of the community controls [5]. Post-discharge mortality rates as high as 17�9% and
36�5% have been reported in other African countries such as Kenya and Uganda [4,6]. In
malaria endemic African countries, malaria infection is a major contributor of severe anemia
and is a risk factor for slow hematological recovery that occurs in the community where the
risk remains high [7–10].
Post-discharge malaria chemoprevention (PMC) is the targeted use of antimalarials in chil-
dren with severe anemia to create a malaria prophylactic window period post-transfusion and
during recovery [11]. Similar to seasonal malaria chemoprevention (SMC), PMC clears exist-
ing infections and provides prolonged prophylaxis against new infections [12–15]. A random-
ized clinical trial conducted in Malawi reported that provision of PMC to children aged less
than 5 years with long-acting ACTs during recovery from severe anemia prevented up to 21%
of deaths or hospital readmissions within 6 months after discharge [16]. More recently trials in
Uganda and Kenya found that PMC resulted in 65% reduction in malaria incidence during the
three months intervention period after successful treatment with blood transfusion and paren-
teral antimalarial drugs [11,17].
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Utilizing community health workers (CHW) to deliver interventions for childhood diseases
such as pneumonia and malaria has been reported to be effective in reducing childhood mor-
tality and improved access [18]. Compared to facility-based delivery, provision of intermittent
preventive therapy (IPT) in pregnant women and children by CHWs in the community, has
also been shown to reduce malaria prevalence and incidence [19,20]. However, this delivery
strategy may have some challenges with sustainability due to inadequate supervision, low
remuneration and irregular supplies among others [21]. Although facility based interventions
have been effective at reducing disease complications [19], they are costly and challenging to
deliver for the health system [22].
PMC is an intervention that could offer substantial public health gains in managing under-
five children who are at risk of dying. Although PMC is a relatively simple intervention, imple-
mentation will require appropriate delivery strategies so that it reaches the population that
need it most. However, a major concern is how it can be delivered in an effective and sustain-
able way [16]. However, unlike other health interventions delivered to children through estab-
lished health systems such as the expanded programme on immunization, there is no existing
delivery mechanism for PMC.
The aim of this trial was to identify the most effective delivery mechanism for PMC by com-
paring community and facility-based delivery systems with and without reminders using




The study was conducted at Zomba central hospital (ZCH), a referral government hospital
with high pediatric admissions rates due to severe malarial anemia located in southern Malawi
with perennial malaria transmission. The hospital provides health services to a population of
over one million and it is the only government health facility that provides blood transfusions
and health services in Zomba district free of charge. Zomba Central Hospital was selected
because previous related studies had been conducted there and is was particularly suitable for
the delivery trial because of the existing linkages with community based health care providers
and rural clinics within their catchment areas. Fig 1 is a map depicting the study area.
Study design and participants
This was a five-arm open label cluster-randomized trial. Children aged less than five years who
were admitted to ZCH pediatric ward were included if they had severe anemia (defined as a
hemoglobin (Hb) concentration of<5g/dL) [23], and having received the standard in-hospital
care which included a blood transfusion, intravenous artesunate and antibiotics, if bacterial
infection was suspected. Once stable, all children received oral lumefantrine-artemether (AL)
and caregivers were provided with information regarding the trial procedures, medication and
follow up. We excluded children with other specific causes of anemia such as trauma, those
with confirmed sickle cell or heart disease and those who resided out of the catchment area.
After obtaining informed consent in the local language of Chichewa from their legal guardians,
we collected socio-demographic information and medical history using questionnaires and
performed a physical examination. We collected a blood sample from a finger prick to check
Hb using the hemocue 301 (Angelholm, Sweden) and malaria slides for microscopy. After
enrolment, the study participants were traced to their home to collect GPRS positions for fol-
low up and ascertain distance from the hospital.
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Randomization and procedures
The unit of randomization was the village cluster and it was computer-generated by the trial
statistician prior to the trial. All of the 1486 villages which were defined to be in the catchment
area of ZCH were randomized to each delivery method, as it was not known which village pro-
spective participants would reside prior to the study. Therefore, all children from the same vil-
lage cluster would be assigned to the same delivery arm. The villages were randomized to one
of the following five arms: 1) community-based without an SMS reminder (Com + No SMS);
2) community-based with an SMS reminder (Com+SMS); 3) community-based with an HSA
reminder instead of SMS reminder (Com+HSA); 4) facility-based delivery without SMS
reminder (Fac-SMS); or 5) facility-based delivery with SMS reminder (Fac+SMS). Detailed
descriptions of the methods have been provided in Table 1 and published (S4 File) [24].
Text message reminder. In the SMS arms, the text of the SMS was customized for each
child with the following message “Remember to give (child’s name) medication starting from
tomorrow for three days.” It was translated into the local language of Chichewa, the most
widely spoken language in Malawi. The reminder was pre-tested on a random sample of care-
givers coming with their children to the pediatric out-patient department prior to commence-
ment of the trial. Considering that this was an implementation trial, we wanted to reflect the
“real life” situation and therefore mobile phones were not provided to caregivers. However, for
all study participants; we collected mobile phone numbers of the nearest contact person. Con-
senting caregivers were instructed to inform the owners of the mobile phone numbers that
Fig 1. A map of Zomba depicting the study site catchment area.
https://doi.org/10.1371/journal.pone.0255769.g001
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their child was participating in the trial Caregivers and study staff was aware of the allocation.
However, the study statistician who performed the analyses was blinded to treatment
allocation.
Study medication
The study medication was co-formulated 20 mg dihydro-artemisinin and 160 mg piperaquine
(Eurartesim1, Sigma-Tau, Italy) dispersible tablets prescribed in standard doses for three days
every month. The monthly treatment courses were prescribed at two (PMC-1), six (PMC-2)
and ten weeks (PMC-3) after discharge enrolment regardless of the presence of symptoms.
The maximum number of doses that could be administered was nine. Standardized verbal
instructions about administration were given to the primary caregiver and specific dates of
administration were documented in the child’s health book and the drug blister pack. After
enrolment, all the participants were requested to come back to the study clinic at 15 weeks for
the end of study assessment.
Follow-up procedures. One to three days after the child was supposed t be given the
last dose of each course of medication, field workers made unannounced home visits to col-
lect blister packs and assess if study medication was indeed given to the child participating
in the trial. If the caregiver was not at home, they were contacted and visits were made when
they were at home. The number of tablets remaining in the blister packs was recorded and if
none were remaining “0” was recorded. If the blister pack was missing the field worker
probed to assess if the medicine was given to the child or not. In addition, assessment for
adverse events was made and children were referred to the nearest health facility if they
were sick. Data were entered directly into questionnaires in handheld tablets programmed
with open data kit (ODK) electronic case report forms (eCRF). Stata 15 was used for
analysis.






PMC drugs given at discharge without SMS reminders: The guardian received all
drugs for PMC-1, PMC-2, and PMC-3. They were instructed on how and when to
give these drugs to the child when being discharged from the hospital.
Com+SMS PMC drugs given at discharge with SMS reminders: The guardian received all
drugs for PMC-1, PMC-2 and PMC-3 and was instructed on how and when to give
the drugs to the child. Additionally, they were reminded via SMS to give the drugs
to the child a day before each treatment course was due.
Com+HSA PMC drugs given at discharge with HSA reminders: The guardian receives all
drugs for PMC-1, PMC-2 and PMC-3 and was instructed on how and when to give
the drugs to the child. Additionally, HSAs who are officially government-
supported community-based health workers were reminded via SMS to go and




PMC drugs collected from the hospital: At discharge, the guardian was requested
to return to the outpatient department (OPD) of the hospital each month to collect
drugs (a treatment course at each time) for PMC-1, PMC-2, and PMC-3. They did
not receive any form of reminder other than what was documented in the child’s
health card.
Fac+SMS PMC drugs collected from the hospital with SMS reminders: At discharge, the
guardian was requested to return to the OPD each month to collect drugs (a
treatment course at each time) for PMC-1, PMC-2, and PMC-3. Additionally, they
were reminded via SMS to come to the clinic to collect drugs a day before each
treatment course was due.
https://doi.org/10.1371/journal.pone.0255769.t001
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Sample size
The study was designed to determine whether delivery of PMC through community-based
methods resulted in higher adherence than when delivered through facility-based methods
and the sample size was based on this. The main effects of “place of delivery” and “use of
mobile phone reminders” were of primary interest. It was estimated that each village cluster
would contribute 2 to 4 children with severe anemia. We assumed an intra-cluster correlation
coefficient (ICC) of 0.1 and allowing for 20% loss-to-follow-up or efficiency loss due to varying
cluster sizes, a sample size of 125 clusters (villages) of an average of 3 children per village (i.e.
75 children per arm and 375 overall), had 80% power to detect a 25% absolute increase in cov-
erage from an estimated 50% in the standard out-patient groups to 75% in the arms supported
by mobile phone reminders (α = 0.05). The ICC of 0.1 is slightly more conservative than the
ICC in a previous trial of delivery approaches for IPTc in the Gambia (0.08). A statistical analy-
sis plan (SAP) was written and agreed upon by all investigators before the data were analyzed.
However, additional analyses were included in the SAP during analysis to explore effects of
different cut offs of adherence.
Statistical considerations
We used appropriate descriptive statistics to summarize data, with mean or median (IQR) for
continuous data, and frequencies and percentages for categorical data. For the primary out-
come, our analysis was by intention to treat at cluster and participant levels. We used Poisson
regression for the total number of doses administered. The unadjusted and adjusted incidence
rate ratios (IRR) measuring the percentage of children receiving PMC according to schedule
in each arm were obtained and compared between arms and the 95% CI for the IRR have been
reported. The estimates of the IRR were adjusted for baseline characteristics and accounted for
clustering with 95% CIs are provided for all measures of effect.
We also employed a factorial design analysis for further analysis to investigate the interac-
tion between the effects of community compared to facility delivery and the pooled effect of
SMS; and interaction terms were included in models to assess the strength of interaction. We
also did several subgroup analyses for the primary and secondary outcomes adjusted for clus-
tering, socioeconomic and demographic variables stratified by each intervention arm with the
Fac-SMS group as the reference group.
Our primary outcome of the study adherence to 7 to 9 doses of the study drugs. The sec-
ondary outcomes of the trial were: 1) the proportion of those with medium adherence defined
as administration of 4 to 6 doses of the study drug; 2) the proportion of those with low adher-
ence defined as the administration of less than 3 doses of the study drugs; 3) all-cause mortality
and 4) all cause sick visits.
For the secondary outcomes, the levels of adherence were compared between the five
groups. Full details of the study design and statistical methods are provided in detail in the pro-
tocol [24], which is available as S4 File.
Ethical approval
The study was approved by the research ethics committees of the College of Medicine in
Malawi (COMREC, approval number P�02/15/1679 and the Regional Ethics Committee of
Norway, approval number 2015/537 (REK Vest). Written informed consent was obtained
from legal guardians of the study participants prior to enrolment. The trial was registered at
ClinicalTrials.gov (identifier: NCT02721420).
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Results
Between 24 March 2016 and 09 October 2018, a total of 667 children hospitalized with severe
anemia were screened for eligibility and 375 children from 329 villages were eligible and
enrolled (Com+ No SMS = 69; Com+SMS = 75; Com+HSA = 79; Fac-SMS = 77; Fac+SMS =
75). A total of 351 children (93.6%) were followed successfully until the end of the study; care-
givers of four children (1.1%) withdrew consent prior to the first home visit while four chil-
dren died and twenty did not attend the end of study visit at 15 weeks. Fig 2 is a CONSORT
flow chart depicting the enrolment and follow up procedures of the trial.
Table 2 provides a summary of the baseline characteristics of the trial participants. There
was a good balance in the baseline characteristics across the arms. The overall median age and
weight for all the participants were 29 (IQR 19–39) months and 11.3 (IQR 9.6–13.2) kg, respec-
tively. There were generally more males in each arm except in the Fac+SMS arm (48% male).
The proportion of participants with a history of having had a blood transfusion in the preced-
ing month to enrolment was low (1.6%) across all the arms (Table 1). Over three quarter of
children used insecticide-treated nets (ITN) the previous night prior to admission. None of
the households had insecticide residual spraying. Fever was the most common presenting
symptom and the mean hemoglobin was 7.9g/dL (sd 1.4).
Mobile phone ownership in the household or with a neighbor was reported in 39.7% of the
caregivers, with the Fac+SMS arm reporting highest (45.2%). The mean distance to the hospi-
tal was similar among all the arms (19.7 ±SD 9.5 km). Out of the 150 participants who were
expected to receive SMS reminders, only 25 [18.0% (10 in COM+SMS and 15 in FAC+SMS)]
reported to have received at least one SMS.
Adherence
The primary outcome was to compare the PMC delivery across the five intervention arms. The
endpoint is based on the total number of doses that were actually used. Adherence to all PMC
courses was reported in 63.1% of all the children. A higher proportion of children in the com-
munity-based arms reported full adherence to compared to facility-based arms (70.6% versus
52.7%, IRR = 1.24, 95% CI 1.06–1.44, p = 0.006). Children receiving PMC in the community
in the SMS arm reported the highest proportion of full adherence (79.7%) compared to those
in the community but receiving no SMS (63.2%), Com+HSA (68.4%), Fac-SMS (51.3%) and
Fac+SMS (52. %) in the univariate analysis. The proportion that was administered at least six
doses representing medium adherence was 22.1% among all the children and Fac-SMS arm
had the highest proportion of medium adherence (27.6%), and Com+SMS arm (12.2%) lowest
for medium adherence. On the other hand, only 2.9% of the children reported very low adher-
ence which was representing less than 30% of the total doses (Table 3, S2 and S3 Files).
In the mixed effects model, village did not have a significant random effect, the likelihood
ratio test was 2.9e-05, p = 0.498. In fact the Intra-Cluster Correlation coefficient (ICC) was
very small 7.56e-06, indicating that there were no correlations for individuals coming from the
same village relative to those of different villages. Thus, the available data is as good as the inde-
pendent data and give the same results as independent data analysis.
When modelled as count data to assess whether the incidence of number of doses used per
patient differ across the groups, a mixed effects Poisson regression was fit to the data. When
PMC was delivered through the community-based methods, adherence was greater than facil-
ity-based methods (IRR = 1.24; 95%CI 1.10, 1.44 p = 0.001) and this was observed in both the
SMS recipients (IRR = 1.41; 95%CI 1.21, 1�64, p<0.001) and in the non-SMS recipients
(IRR = 1.37; 95%CI 1.18, 1.61, p<0.001) (Figs 3 and 4, Table 4).
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Fig 2. Consolidated Standards of Reporting Trials (CONSORT) flow diagram of the PMC delivery trial.
https://doi.org/10.1371/journal.pone.0255769.g002
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Overall, a total of 83.6%, 84.1% and 78.0% of the children received complete courses of
PMC1, PMC2 and PMC3 respectively. Generally, most of the children who received the first
dose of each PMC course also received the second and the third dose. A small proportion
(1.3%) received the first and second dose but not the third dose of PMC 1, only one participant
(0�3%) took only the first dose of PMC 2 and another one (0.3%) took only the first and second
doses of PMC 2. All participants who took the first course of PMC 3 completed all the three
doses.
Table 2. Baseline characteristics of trial participants.
Characteristic Com+ No SMS Com+SMS Com+HSA Fac+ No SMS Fac+SMS Overall
N = 69 N = 75 N = 79 N = 77 N = 75 N = 375
Participant age in months, median (IQR) 30 (19–40) 30 (23–38) 28 (18–39) 29 (20–38) 28 (16–38) 29 (19–39)
Weight in kg, median (IQR) 12.0 (9.9–3.9) 11.4 (10.0–13.5) 11.4 (9.9–12.5) 11.0 (9.9–12.7) 11.3 (9.6–13.2) 11.3 (9.6–13.9)
Height in cm, median (IQR) 86 (78–92) 84 (79–89) 84 (75–91) 83 (77–90) 84 (77–91) 84 (77–91)
Male, n (%) 37 (53.6) 48 (64.0) 49 (62.0) 42 (54.6) 36 (48.0) 212 (56.5)
Previous transfusion, n (%) 1 (1.5) 2 (2.7) 0 (0.0) 1 (1.4) 2 (2.7) 6 (1.6)
Malaria in previous month n (%) 10 (14.5) 9 (12.2) 6 (7.5) 5 (6.9) 4 (5.5) 34 (9.2)
Slept under ITN previous night, n (%) 52 (75.4) 54 (72.0) 64 (81.0) 62 (80.5) 55 (73.3) 287 (76.5)
Diarrhoea on admission, n (%) 11 (15.9) 12 (16.2) 18 (22.7) 15 (20.6) 14 (19.2) 70 (19.0)
Fever on admission, n (%) 63 (91.3) 69 (92.0) 74 (93.7) 60 (78.0) 69 (92.0) 335 (89.3)
Vomiting on admission, n (%) 26 (37.7) 24 (32.4) 31 (39.2) 17 (23.3) 29 (39.7) 127 (34.5)
Received at three doses of parenteral artesunate, n (%) 69 (100) 75 (100) 79 (100) 77 (100) 75 (100) 375 (100)
Difficulty taking medication, n (%) 14 (22.2) 22 (34.4) 21 (28.7) 19 (29.7) 14 (21.5) 90 (27.4)
Hb at enrolment in g/L, mean (Sd) 7.7 (1.3) 7.9 (1.5) 8.1 (1.6) 7.9 (1.3) 8.1 (1.3) 7.9 (1.4)
Hb at end of study in g/L, mean (Sd) 11.3 (1.5) 11.7 (1.4) 11.6 (1.4) 11.5 (1.5) 11.3 (1.8) 11.5 (1.5)
Guardian age in years, median (IQR) 28 (23–36) 26 (22–34) 27 (23–33) 27 (23–35) 27 (22–34) 27 (22–34)
Literate legal guardian, n (%) 50 (72.5) 46 (63.0) 54 (68.4) 50 (67.6) 52 (72.6) 253 (68.8)
Ownership of mobile phone, n (%) 28 (40.6) 28 (38.4) 28 (35.4) 29 (39.2) 33 (45.2) 146 (39.7)
Wealthy SES, n (%) 10 (14.5) 16 (21.6) 13 (16.5) 15 (20.6) 19 (26.0) 73 (19.8)
Distance to hospital in km, mean (Sd) 19.6 (8.9) 19.4 (8.9) 19.5 (10.2) 20.5 (8.5) 18.2 (9.5) 19.7 (9.2)
https://doi.org/10.1371/journal.pone.0255769.t002
Table 3. Levels of adherence to DHP across all the trial arms.
Level of adherence Total doses Com+ No SMS n (%) Com+ SMS n (%) Com+ HAS n (%) Fac+ No SMS n (%) Fac+ SMS n (%) Total n (%)
Very low (< 30% uptake) 0 1 (1.5) 2 (2.7) 1 (1.3) 4 (5.3) 2 (2.7) 10 (2.7)
1 0 (0) 0 (0) 1 (1.3) 0 (0) 0 (0) 1 (0.3)
2 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Total 1 (1.5) 2 (2.7) 2 (2.6) 4 (5.3) 2 (2.7) 11 (2.9)
Low (30% uptake) 3 7 (10.3) 4 (5.4) 6 (7.6) 11 (14.5) 13 (17.6) 41 (11.1)
4 0 (0) 0 (0) 0 (0) 0 (0) 0(0) 0 (0)
5 1 (1.5) 0 (0) 0 (0) 1 (1.3) 1 (1.4) 3 (0.8)
Total 8 (11.8) 4 (5.4) 6 (7.6) 12 (15.8) 14 (18.9) 44 (11.9)
Medium (60% uptake) 6 15 (22.1) 9 (12.2) 16 (20.3) 21 (27.6) 18 (24.3) 79 (21.3)
7 1 (1.5) 0 (0) 0 (0) 0 (0) 1 (1.4) 2 (0.5)
8 0 (0) 0 (0) 1 (1.3) 0 (0) 0 (0) 1 (0�3)
Total 16 (23.5) 9 (12�2) 17 (21.5) 21 (27.6) 19 (25.7) 82 (22.1)
Full (100% uptake) 9 43 (63.2) 59 (79.7) 54 (68.4) 39 (51.3) 39 (52.7) 234 (63.1)
Total 43 (63.2) 59 (79.7) 54 (68.4) 39 (51.3) 39 (52.7) 234 (63.1)
Total 68 (100) 74 (100) 79 (100) 76 (100) 74 (100) 371 (100)
https://doi.org/10.1371/journal.pone.0255769.t003
PLOS ONE Adherence to post-discharge malaria chemoprevention (PMC)
PLOS ONE | https://doi.org/10.1371/journal.pone.0255769 September 10, 2021 9 / 16
Fig 4. Forest plots illustrating adherence to PMC in each trial arm.
https://doi.org/10.1371/journal.pone.0255769.g004
Fig 3. Kaplan Meir curves illustrating the adherence by the total number of PMC doses that were administered in each trial
arm.
https://doi.org/10.1371/journal.pone.0255769.g003
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Community-based delivery arms had the highest proportions of participants receiving
PMC2; (86.4 to 91.9%) and PMC3 (78.4 to 89.4%) compared to facility-based arms; who
reported up to 78.7% receiving PMC2 and less than 70% for PMC 3. There were no significant
differences in the proportion of participants across the arms in administration taking the
PMC1 (p = 0�56) and PMC2 (p = 0�08) but administration of PMC 3 was statistically different
across all the groups.
As shown in Figs 3 and 4, community delivery utilizing HSA reminders resulted in higher
adherence compared to delivery in the health facility (IRR = 1.32; 95%CI 1.14, 1.54, p<0.001).
However, there was no evidence that SMS reminders resulted in greater adherence compare to
the arms that did not receive the SMS (IRR = 1.03; 95%CI 0.88, 1.21, p = 0.7.
There was no difference in adherence between facility-based delivery with SMS and without
SMS (IRR = 1.16; 95%CI 0.99,1.37, p = 0.07) (Fig 3) and there was no evidence of interaction
between the use of SMS and delivery strategy (Facility/community) (p = 0.88).
There were total of four deaths (overall mortality of 1.1%); two each in the Com-SMS and
Fac+SMS. Two deaths were caused by severe anemia; one due to sepsis and one death caused
by drowning. The total number of reported sick visits was 90 of which 46.7% were due to
uncomplicated malaria. The lowest number of adverse events was observed in the Com+HSA
arm. The number of deaths was too low to make meaningful association to adherence.
Discussion
In this study, we found that children who had their monthly DHP in the community provided
by caregivers irrespective of reminders resulted in 24% higher adherence compared to facility-
based delivery where caretakers were asked to return to the clinic to collect their 2nd and 3rd
course of PMC. These findings are consistent with findings reported from other African coun-
tries. Studies in Kenya, Uganda and Ghana reported that malaria treatment distributed by
CHWs resulted in reduced malaria incidence and increased access to treatment [22,25,26].
Similarly, in Malawi, community delivery of sulfadoxine-pyrimethamine (SP) for intermittent
preventive therapy in pregnancy IPTp by CHWs improved coverage from 41.5% to 82.9%
however it was noted that this led to a reduction in antenatal care (ANC) attendance [27]. In
the Gambia, delivery of intermittent preventive therapy in children (IPTc) by CHWs also
achieved higher coverage, cost-effectiveness and reduced symptomatic malaria cases [20].
Although utilizing CHWs has been supported by WHO and has proved to be effective for
high adherence and reduced incidence of disease, the effectiveness has shown to decline for
Table 4. Poisson regression model excluding PMC 1 with an interaction term in factorial design analysis for adherence between a) community compared to facility
and b) SMS compared to no SMS.
Strategy Crude Adjusted
IRR (95% CI) p-value IRR (95% CI) p-value
Pooled Facility Reference - 1 -
Community - - 1.24 (1.06, 1.44) 0.006
No SMS Reference - 1
SMS - 1.03 (0.88, 1.21) 0.677
By arm Fac+ no SMS (Ref) Reference - 1 -
Com+ No SMS 1.33 (1.14,1.54) <0.001 1.37 (1.18,1.61) <0.001
Com+SMS 1.37 (1.19,1.59) <0.001 1.41 (1.21,1.64) <0.001
Com+HSA 1.29 (1.12,1.5) 0.001 1.32 (1.14,1.54) <0.001
Fac+SMS 1.12 (0.96,1.31) 0.140 1.16 (0.99,1.37) 0.066
https://doi.org/10.1371/journal.pone.0255769.t004
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subsequent doses. In Mali, seasonal malaria chemoprevention (SMC) delivered through rou-
tine programmes utilizing existing CHWs reduced malaria prevalence; 84% of the targeted
children received the first course but only 54% received four complete SMC courses [28].
Another study reported that completion of all the three doses of IPTc was similar (91.6% ver-
sus 91.7%) in community delivery compared to delivery at health centers [29]. Utilizing HSAs
has its own challenges and requires additional resources for training, supervision and incen-
tives and this may be challenging for PMC delivery [20,30]. In addition, children receiving
PMC will not be in the scheduled work plans for HSAs to incorporate. In our setting, it has
been reported that HSAs are motivated to provide reminders for PMC [31]. However, despite
this motivation, our study still showed that less than half of the HSAs conducted the required
home visit reminders. Many of the reported challenges include inability to locate the child,
high existing workload, limited training, supervision, and poor community acceptance
[31,32].
Whereby there are limited studies that have examined adherence to medication when utiliz-
ing caregivers to administer longer-term malaria interventions at home, in our study, we
found that community-delivery utilizing caregivers resulted similar adherence without requir-
ing HSA reminders. One study in Sierra Leone reported that caregivers are capable of adminis-
tering anti-malarial medication to the children with basic instructions and supervision of the
first dose by the CHW [33]. Caregivers were able to administer monthly doses without addi-
tional reminders and this is important because it does not require additional resources. A qual-
itative study examining the acceptance of PMC among caregivers in Malawi reported that
caregivers had a higher preference and confidence to be given all the medication to administer
to their children without any additional reminder because HSAs and phones were unreliable
and collecting medication from the hospital was very challenging [34]. However, the concern
with this method is poor storage conditions, ensuring that medication will be only be adminis-
tered as prescribed to the child and not others and possible side effects of the drugs [34].
Use of mobile phone reminders has been hailed as an important tool to achieve adherence,
optimal treatment response, case management and outcomes in resource poor settings such as
SSA [35,36]. However, we found that SMS did not have that added effect on adherence. In
rural Malawi, provision of SMS to health workers or mothers has been reported to not have a
significant effect on adherence and improvement of management of common childhood ill-
nesses with only up to 46�5% receiving SMSs [37,38]. This is rather low compared to similar
trials in Kenya where providing SMS was effective when 91% received them [39,40]. Chal-
lenges reported with implementing mobile health (mhealth) interventions in resource poor
settings such as Malawi include poor network coverage, access, and inability to charge mobile
phones, literacy and low phone ownership [41].
Our findings are important because PMC is a relatively new intervention in the Malawian
and other developing countries health care system where established delivery systems cur-
rently do not exist. Because the timing of PMC medication administration is sensitive, it
would be a challenge for a caregiver to rely on receiving timely reminders on a personal phone
or rely on others to receive the reminder and pass on the message. A study in Tanzania
reported that unsupervised malaria treatment given at home by caregivers was effective with-
out the utilization of any reminders [30]. Contrasting to this, caregivers have a higher prefer-
ence and confidence to be given all PMC medication to administer at home without any
reminders [34]. In this case, community-based delivery strategies where the medication is
given to the caregivers may be the most successful strategy for this promising intervention.
Although we found that SMS reminders had no effect on adherence, it must be noted that
the proportion of caregivers that reported received the SMS reminder was very low. This was a
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major limitation in our study as we were not able to conclusively state that they are not effec-
tive in improving adherence regards to PMC in our setting.
Conclusion
This is the first study to assess adherence to PMC, which is an innovative intervention for
managing sick children during the post-discharge period. We found that using community-
based strategies, caregivers were able to administer PMC medication to their children without
additional reminders. As they routinely administer medication to their children at home, this
may be a cost-effective strategy for delivery of PMC. Although utilizing HSAs has proven to be
effective for improving adherence for other malaria interventions, adherence to subsequent
doses has tended to decline and may remain challenging for PMC delivery utilizing HSAs
reminders, which is interval sensitive.
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